Revier Therapeutics

Revier Therapeutics is a biotechnology company focused on developing next-generation targeted protein degradation (TPD) therapies. The company utilizes its proprietary Revier-Glue platform to discover and develop small molecule molecular glues that can selectively degrade disease-causing proteins. Revier's primary focus is on addressing high-unmet-need areas, particularly neurodegenerative diseases like Alzheimer's and Parkinson's, as well as various oncology indications. By leveraging its expertise in protein homeostasis, the company aims to create transformative treatments for conditions previously considered undruggable. Headquartered in San Diego, Revier is led by an experienced management team with a track record of successful drug development.